GlassScriptPhysician profile
Fatma Akmese
NPI 1508800830
$4,560.58
in general payments reported to CMS, 2019-2025
18 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.58 · 2020: $91.57 · 2021: $1,088 · 2022: $1,059 · 2023: $1,506 · 2024: $346 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $988.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $644.28 | 2021-2025 | Arexvy, Trelegy Ellipta, Bexsero |
| Abbvie INC. | $613.66 | 2021-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $423.46 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $346.08 | 2021-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.71 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $291.31 | 2019-2025 | Freestyle Libre 3 |
| Indivior INC. | $271.50 | 2021-2024 | Sublocade |
| Alkermes, INC. | $203.00 | 2022-2023 | Vivitrol |
| Orexo US, INC. | $113.20 | 2021-2023 | Zubsolv |
| Gilead Sciences, INC. | $112.10 | 2023 | Epclusa |
| Phathom Pharmaceuticals, INC. | $82.60 | 2024-2025 | Voquezna |
| Pfizer INC. | $36.24 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.60 | 2023-2025 | Xifaxan |
| Mannkind Corporation | $20.33 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.01 | 2019 | |
| Braeburn INC. | $19.74 | 2024 | Brixadi |
| Novartis Pharmaceuticals Corporation | $17.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatma Akmese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.